Brief: Cumberland Pharmaceuticals Announces FDA Clearance Of IND For New Treatment Of Idiopathic Pulmonary Fibrosis
23/05/2023 14:20
May 23 (Reuters) - Cumberland Pharmaceuticals Inc
CPIX.O :
* CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND
FOR
NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
* CUMBERLAND PHARMACEUTICALS INC - INITIATING PHASE II
FIGHTING
FIBROSIS(™) CLINICAL TRIAL
Source text for Eikon: ID:nPn7N3ZYa
Further company coverage: CPIX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Cumberland Pharmaceuticals
See all newsBrief: Cumberland Pharmaceuticals Announces Assist-Ssc Trial Top-Line Results
Cumberland Pharmaceuticals Q2 loss widens after Apotex transaction
Brief: Cumberland Pharmaceuticals Announces Special Dividend Of $1.50 Per Share
Cumberland Pharmaceuticals Q1 revenue up 5%; to sell FDA‑approved brands to Apotex for $100 mln
NASDAQ RESUMED AT 09:38 AM